Next Article in Journal
Knowledge, Attitudes, Intentions and Vaccine Hesitancy among Postpartum Mothers in a Region from the Northwest of Romania
Next Article in Special Issue
Trends in Vaccine Completeness in Children Aged 0–23 Months in Cape Town, South Africa
Previous Article in Journal
Knowledge, Attitudes, and Willingness of Healthcare Workers in Iraq’s Kurdistan Region to Vaccinate against Human Monkeypox: A Nationwide Cross-Sectional Study
Previous Article in Special Issue
Association between Vaccination Status for COVID-19 and the Risk of Severe Symptoms during the Endemic Phase of the Disease
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Attitudes toward COVID-19 and Other Vaccines: Comparing Parents to Other Adults, September 2022

1
Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, MD 21205, USA
2
Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
3
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
4
Department of Pediatrics, SUNY Upstate Medical University, Syracuse, NY 13210, USA
5
Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
*
Author to whom correspondence should be addressed.
Vaccines 2023, 11(12), 1735; https://doi.org/10.3390/vaccines11121735
Submission received: 5 October 2023 / Revised: 8 November 2023 / Accepted: 18 November 2023 / Published: 21 November 2023

Abstract

:
Few analyses of COVID-19 vaccine attitudes also cover routine vaccines or focus on parents. In this cross-sectional study, we surveyed US adults in September 2022, immediately following the authorization of updated bivalent COVID-19 boosters for adults but before their authorization for children. The vaccine attitudes of parents were compared to other adults. Fewer parents were up-to-date on COVID-19 vaccines than other adults (54% vs. 67%), even after adjusting for age, education, and race/ethnicity (Adjusted Odds Ratio: 0.58; 95% Confidence Interval: 0.45–0.76). More parents had concerns about COVID-19 vaccines’ safety in children (67% vs. 58%; aOR: 1.59; 95%CI: 1.23–2.06) and vaccine ingredients (52% vs. 45%; aOR: 1.41; 95%CI: 1.09–1.81), and more parents perceived COVID-19 in children to be no worse than a cold or the flu (51% vs. 38%; aOR: 1.56; 95%CI: 1.22–2.01). Fewer parents supported COVID-19 vaccine school requirements (52% vs. 57%; aOR: 0.75; 95%CI: 0.58–0.97) and perceived high vaccine coverage among their friends (51% vs. 61%; aOR: 0.60; 95%CI: 0.46–0.78). However, three-quarters of parents intended their child to receive all routinely recommended vaccines, whereas only half of adults intended to receive all routinely recommended vaccines themselves. To improve parental informed vaccine decision-making, public health must ensure pediatric providers have updated resources to support their discussions of vaccine risks and benefits with their patients’ parents.

1. Introduction

Two COVID-19 mRNA vaccines have received Emergency Use Authorization (EUA) for children in the United States (US): Pfizer-BioNTech (Comirnaty) [1,2,3,4] and Moderna (Spikevax) [4,5]. Comirnaty was fully approved for adolescents 12 years and older in July 2022 [6]. Updated bivalent formulations of both were authorized in August 2022 to boost protection against circulating strains, initially just as booster doses for adults (Moderna and Pfizer) and adolescents (Pfizer) [7]. The EUAs for the updated bivalent vaccines were amended in October 2022 to include older children [8] and in April 2023 to include all children at least 6 months old, coinciding with an updated recommendation for all persons who have not yet done so to receive an updated vaccine [9]. Updated vaccine coverage remains poor, especially among children: as of 26 April 2023, just 5% of children 5–11 years old and 8% of adolescents 12–17 years old had received a bivalent dose, compared to 20% of adults [10]. The strongest predictors of parental intention to vaccinate their children against COVID-19 are the perceived benefits of the vaccine and previous acceptance of other routine vaccines for their children [11].
Although many parental vaccine concerns existed before the pandemic [12], and vaccine attitudes among US parents may have initially improved at the outset of the pandemic [13], overall, the pandemic seems to have had a negative impact on vaccine confidence. Vaccines unfortunately became a polarizing political issue during the pandemic [14], which, along with pandemic fatigue [15], has increased hesitancy to receive COVID-19 vaccines [16,17] and perhaps routine vaccines as well [18]. Frequent collection and review of representative survey data is needed to understand trends in vaccine hesitancy, especially if the drops in routine vaccine coverage from the early pandemic are to be regained [19,20].
We previously conducted a national panel survey in September 2021 [21], just before Pfizer’s EUA for children 5–11 years old [3], which included an analysis of the vaccine attitudes of parents compared to other adults [22]. About two-thirds (69%) of parents of children aged 2–17 years old had received at least one COVID-19 vaccine. Parents had lower odds of being vaccinated against COVID-19 than other adults, even after adjusting for associated sociodemographic characteristics such as age (aOR: 0.65; 95%CI: 0.49–0.87). Parents also had lower odds of having high confidence in routine vaccines (aOR: 0.76; 95%CI: 0.59–0.98).
Herein, we describe findings from an analysis of another national panel survey conducted in September 2022 [23], a year after our previous survey [21,22], and immediately after the EUA of updated bivalent boosters for adults [7] but before their authorization for children [8]. The main focus of this analysis was to compare the vaccine attitudes of parents to other adults, both for COVID-19 and for other recommended vaccines.

2. Materials and Methods

2.1. Study Design

A national panel survey was administered between 1 and 12 September 2022, in English and Spanish, using Ipsos KnowledgePanel [24], the largest probability-based online panel in the US. Ipsos uses address-based sampling techniques to recruit members to ensure the geodemographic composition of the panel mimics the adult US population. Stratified random selection, enrollment quotas, and survey weights ensured that the sociodemographic distribution of our sample remained representative of the adult US population even while oversampling Hispanic and Black respondents by 50% to increase the power to detect differences by race/ethnicity. We have successfully used Ipsos KnowledgePanel for related surveys previously [21,22,25,26]. More detail on the methodology of this survey is described in a previous publication [23], as well as in the STROBE checklist (Table S1) [27]. The Institutional Review Board of the Johns Hopkins Bloomberg School of Public Health considered this study public health surveillance and not human subject research.

2.2. Variables

One primary outcome of this survey was COVID-19 vaccination status. The survey began by asking respondents to identify themselves as either up-to-date (i.e., fully vaccinated and boosted); vaccinated but not up-to-date (e.g., have not gotten a booster yet); not vaccinated against COVID-19; or preferring not to say (a response only given by 3% of the sample and thus treated as missing).
This survey also measured attitudes about vaccines for both children and adults, including constructs such as perceived susceptibility to and severity of vaccine-preventable diseases and the importance of COVID-19 vaccines. Among those not yet up-to-date on COVID-19 vaccines nor intending to get up-to-date as soon as possible, respondents identified their concerns and other reasons for not vaccinating. Confidence in sources of COVID-19 information, cumulative COVID-19 disease prevalence (ever having COVID-19 disease), and self-reported influenza vaccination were captured. Trust in the Centers for Disease Control and Prevention (CDC) was measured using a 14-item scale previously developed and validated [28]. A Cronbach’s alpha coefficient of 0.93 indicates the reliability of this scale. Further methodological details on the use of this scale are described in a previous publication [23].
Respondents were asked how many children (less than 18 years old) they had and the age of each child. Parents of at least one preteen 11–12 years old were given additional survey items pertaining to these children. Parents of children under 5 years old (who did not also have a child 11–12 years old) were given similar items pertaining to their child(ren) under 5 years old. These two age ranges were targeted to reflect the ages at which most vaccines are recommended according to the CDC schedule: most vaccines are given in the first five years of life, including vaccines required for kindergarten by law in many states (e.g., DTaP, polio, MMR, varicella, hepatitis B), though three vaccines (HPV, Tdap, meningococcal) are not recommended until 11 years of age [29]. Survey items measured parental intentions to get their children the vaccines recommended for their age group, confidence in the safety of these vaccines, self-efficacy (confidence they could get their child vaccinated), perceived vaccine knowledge, and specific vaccine concerns. Adults who were not parents of children 0–5 or 11–12 years old were given similar survey items but focused on adult vaccines recommended for themselves (since these adults were likely due the same number or more vaccines than their children), and were split by those 18–50 years old versus over 50 years old, again to reflect the vaccine schedule (e.g., the herpes zoster vaccine is only recommended for adults over 50) [30]. In essence, these four age groups of interest (parents of children 0–5, parents of preteens 11–12, adults 18–50, adults 50+) were made mutually exclusive, with each respondent only receiving the additional survey items for one of the four age groups, with priority given to the smallest group, to avoid redundancy and reduce survey length while maintaining power for precise estimates within each group. So, although all respondents received additional survey items, respondents who were parents of children both 0–5 years old and 11–12 years old were only given the additional survey items corresponding to the 11–12 age group, and adults 18–50 who were also parents of children 0–5 years old were only given the additional survey items corresponding to the 0–5 age group.
Gender, age, race/ethnicity, education, income, employment status, metropolitan statistical area (MSA), region, and political affiliation were among the sociodemographic characteristics available for all respondents. Choices in survey content were influenced by the Health Belief Model [31] and the Social Ecological Model [32].

2.3. Measurement

The sample size for this survey was chosen to approximate the sample size of our previous related Knowledge Panel surveys, which were well-powered to demonstrate attitudinal associations with vaccine status and intentions [21,22,25,26]. Design weights were adjusted using a raking procedure to imitate the US adult population. Hispanic and Black respondents were oversampled to increase power for stratified analyses but down-weighted to reflect their proportion in the population (Table 1). Further details on this weighting technique have been published elsewhere [25].
Sociodemographic characteristics (Table 2) and vaccine attitudes (Table 3) were cross-tabulated against parent status, and vaccine attitudes were also cross-tabulated against oldest child age (comparing older to younger) (Table S2). Odds ratios were calculated. General vaccine attitudes and safety concerns were cross-tabulated against general vaccine intentions (Table 4). Likert and other scale response options were dichotomized to reflect affirmative versus negative (e.g., agree vs. disagree, important vs. not important) to facilitate straightforward analysis and interpretation.
Standard errors for weighted proportions were calculated using Taylor-linearized variance estimation. p-values for cross-tabulations were calculated using the Pearson chi-squared proportion test (α = 0.05). Bivariate odds ratios were calculated using generalized logistic binomial regression with a logit link function. In Table 2, simple logistic regressions featured parent status as the dependent variable and other sociodemographic characteristics as independent variables. In Table 3, multiple logistic regressions featured affirmative survey responses as the dependent variable and parent status as the main independent variable, with the sociodemographic characteristics significantly associated with parent status in Table 2 included as additional independent variables to adjust for potential confounding. Data were analyzed using Stata statistical software (version 16) [33].

3. Results

3.1. Study Population and Survey Weighting

The survey was fielded among 5323 panel members. Of these, 2787 (52%) completed the survey, of which 2561 qualified for the study (based on eligibility criteria and survey quotas). Unweighted and weighted sociodemographic characteristics and vaccination status of the study population are presented in Table 1. Weighted data are generalizable to the adult population of the US.
Table 1. Sociodemographic characteristics and vaccination/disease status of the sample: unweighted and weighted.
Table 1. Sociodemographic characteristics and vaccination/disease status of the sample: unweighted and weighted.
Sociodemographic
Characteristics
Unweighted N (%)Weighted % aSociodemographic
Characteristics
Unweighted N (%)Weighted % a
All2561 (100) Household Annual Income
Gender   <$50,000847 (33.1)29.9
  Female1274 (49.7)51.4  $50,000–75,000452 (17.6)16.4
  Male1287 (50.3)48.6  $75,000–100,000346 (13.5)13.1
Age (years)   $100,000–150,000413 (16.1)17.8
  18–29308 (12)19.9  $150,000+503 (19.6)22.8
  30–44679 (26.5)25.7Political Affiliation
  45–59669 (26.1)23.9  Republican517 (20.2)25.3
  ≥60905 (35.3)30.5  Democrat998 (39.1)32.8
Education   Independent/Other1039 (40.7)41.9
  <High School223 (8.7)9.6Metropolitan Statistical Area Status
  High School589 (23)28.1  Non-Metro276 (10.8)13.4
  Some College757 (29.6)27.1  Metro2285 (89.2)86.6
  Bachelor’s or Higher576 (22.5)19.6Parent Status
  Master’s or Higher416 (16.2)15.5  No Children <18 1794 (70.1)71.4
Race/Ethnicity   At Least One Child <18 767 (29.9)28.6
  White, non-Hispanic997 (38.9)62.8Influenza Vaccination b
  Black, non-Hispanic609 (23.8)12.0  Not Vaccinated1144 (45.2)46.1
  Hispanic838 (32.7)16.9  Vaccinated1386 (54.8)53.9
  Other, non-Hispanic117 (4.6)8.3COVID-19 Vaccination
Region   Not Vaccinated329 (13.3)15.5
  Northeast415 (16.2)17.3  Vaccinated (≥1 dose)2140 (86.7)84.5
  Midwest455 (17.8)20.7COVID-19 Disease
  South1036 (40.5)38.2  Never Had1432 (56.7)55.9
  West655 (25.6)23.8  Ever Had1093 (43.3)44.1
a Weights used iterative proportional fitting so that the sample represented US adults; Black and Hispanic respondents were weighted to adjust for their oversampling (to provide sufficient power for analyses stratified by race/ethnicity). b Respondents reported whether or not they had received an influenza vaccine within the past 12 months; these data were collected prior to the 2022–2023 influenza season, and so should reflect the 2021–2022 influenza season.

3.2. Parent Status

3.2.1. Sociodemographic Characteristics Associated with Parent Status

Nearly 30% of the weighted sample had at least one child less than 18 years old (Table 2). Three sociodemographic factors were associated with being a parent: age, education, and race/ethnicity.
Table 2. Sociodemographic characteristics of parents (of children <18 years of age) versus other adults.
Table 2. Sociodemographic characteristics of parents (of children <18 years of age) versus other adults.
Survey ItemsTotal (%) a
N = 2561
Parent (%) bp-Value cOR (95%CI) d
NoYes
All1007129
Gender 0.17
  Female515054 ref e
  Male495046 0.86 (0.70–1.07)
Age (years) <0.01
  18–29202214 ref e
  30–44261455 6.37 (4.36–9.31)
  45–59242325 1.71 (1.16–2.52)
  60+31406 0.23 (0.14–0.37)
Education (attained) <0.01
  <High School10812 ref e
  High School283024 0.55 (0.37–0.82)
  Some College272824 0.59 (0.40–0.87)
  Bachelor’s202019 0.67 (0.45–0.99)
  Master’s or Higher161420 0.96 (0.64–1.45)
Race/Ethnicity <0.01
  White, non-Hispanic636752 ref e
  Black, non-Hispanic121213 1.46 (1.13–1.88)
  Hispanic171522 1.95 (1.55–2.45)
  Other, non-Hispanic8712 2.23 (1.42–3.50)
Region 0.33
  Northeast171815 ref e
  Midwest212022 1.37 (0.97–1.95)
  South383839 1.27 (0.93–1.73)
  West242424 1.25 (0.90–1.75)
Household income 0.35
  <$50,000303127 ref e
  $50,000–75,000161716 1.07 (0.76–1.49)
  $75,000–100,000131312 1.04 (0.74–1.47)
  $100,000–150,000181719 1.22 (0.88–1.69)
  $150,000+232226 1.32 (0.99–1.77)
Political affiliation 0.27
  Republican252624 ref e
  Democrat333431 0.98 (0.74–1.30)
  Independent/Other424145 1.17 (0.89–1.55)
Metropolitan Statistical Area status 0.85
  Non-Metro131313 ref e
  Metro878787 1.03 (0.74–1.44)
a Column percentages (of total sample N = 2561), weighted for national representativeness. b Column percentages (of parent status) (except for the first row, “All”, which is a row percentage), weighted for national representativeness. c Using the Pearson chi-square test; bold indicates statistical significance (p < 0.05). d Odds Ratio (95% Confidence Interval) of being a parent of at least one child <18 years of age and reporting the sociodemographic characteristics in each row; for example, survey respondents who were 60+ years old had 77% lower odds of being a parent of at least one child <18 years of age than survey respondents who were 18–29 years old; bold indicates statistical significance (p < 0.05). e Reference category for logistic regression of categorical variable.

3.2.2. Vaccine and Disease Status Associated with Parent Status

Parents were less likely to be up-to-date on their COVID-19 vaccines than other adults (54% vs. 67%), even after adjusting for age, education, and race/ethnicity (Adjusted Odds Ratio: 0.58; 95% Confidence Interval: 0.45–0.76) (Table 3). Parents were also more likely to report ever having COVID-19 disease (54% vs. 40%; aOR: 1.50; 95%CI: 1.17–1.93).
Table 3. Vaccine attitudes and values of parents (of children <18 years of age) versus other adults.
Table 3. Vaccine attitudes and values of parents (of children <18 years of age) versus other adults.
Survey ItemsTotal (%) a
N = 2561
Parent (%) bp-Value caOR (95%CI) d
NoYes
All1007129
Vaccination and Disease Status
 Vaccinated against flu within the past year5455520.281.13 (0.88–1.46)
 Vaccinated against COVID-19 (at least one dose)8586820.100.83 (0.56–1.22)
 Up-to-date on COVID-19 vaccines636754<0.010.58 (0.45–0.76)
 Ever knowingly had COVID-19 disease444054<0.011.50 (1.17–1.93)
Scales
 Trust in the Centers for Disease Control and Prevention (CDC)6868670.600.91 (0.70–1.19)
Confidence in sources of information about COVID-19
 My doctor8686860.941.08 (0.74–1.60)
 My local or state health department7474740.861.01 (0.75–1.36)
 Scientists and doctors from the CDC7069710.401.08 (0.81–1.44)
 The Surgeon General6867700.361.10 (0.82–1.46)
 Scientists and doctors from universities7372750.291.07 (0.79–1.45)
 Dr. Anthony Fauci, National Institutes of Health6262620.940.88 (0.67–1.14)
 Dr. Rochelle Walensky, CDC Director 6363610.540.90 (0.69–1.17)
 Dr. David Satcher, Morehouse School of Medicine, Former CDC Director and Surgeon General6262620.980.94 (0.73–1.23)
 My religious leader3130320.321.23 (0.93–1.62)
 Other non-medical people in my community that I trust3131310.881.04 (0.77–1.40)
 What I see on the news374031<0.010.68 (0.53–0.88)
 What I see on social media (Facebook, Twitter, etc.)1312160.051.13 (0.78–1.63)
Agreement with COVID-19 Likert Scale Items (for Adults)
 I worry I may accidentally spread COVID-19 to my family members in the next six months.3029350.010.99 (0.77–1.28)
 I worry I may accidentally spread COVID-19 to my friends, neighbors, or co-workers in the next six months.272532<0.011.05 (0.80–1.38)
 If I get COVID-19, I think it will be severe.1414150.461.00 (0.68–1.46)
 COVID-19 vaccines are important to stopping the spread of infection in the US.7273700.210.90 (0.68–1.20)
 COVID-19 vaccines are important to helping the US get back to a normal life.7172680.120.79 (0.60–1.05)
 Most or all of my family members have gotten vaccinated against COVID-19.6566630.180.84 (0.64–1.10)
 Most or all of my friends have gotten vaccinated against COVID-19.586151<0.010.60 (0.46–0.78)
 If my main doctor were to recommend that I take the COVID-19 vaccine, I’d be likely to take it.4241500.370.90 (0.80–1.02)
 If a close family member were to recommend that I take the COVID-19 vaccine, I’d be likely to take it.3839380.870.94 (0.61–1.43)
 If my close friends were to recommend that I take the COVID-19 vaccine, I’d be likely to take it.3434330.830.98 (0.63–1.54)
 I feel knowledgeable about the COVID-19 vaccine.7678720.010.79 (0.59–1.07)
 I’d like to get more information on COVID-19 vaccines.3030300.920.89 (0.68–1.17)
Agreement with COVID-19 Likert Scale Items (for Children)
 COVID-19 can be a serious disease for some children.8384820.380.99 (0.69–1.41)
 I am concerned about the safety of the COVID-19 vaccine in children.615867<0.011.59 (1.23–2.06)
 Vaccinating children against COVID-19 is important to end the pandemic and get back to normal.6566610.060.73 (0.56–0.95)
 It is better for children to develop immunity to COVID-19 by getting sick rather than by getting a shot.373345<0.011.56 (1.20–2.02)
 COVID-19 in children is no worse than a cold or the flu.423851<0.011.56 (1.22–2.01)
 I would support a requirement for children to be vaccinated against COVID-19 to attend school.5657520.050.75 (0.58–0.97)
Agreement with General Vaccine Likert Scale Items
 I am confident in the safety of vaccines.7980780.510.95 (0.68–1.33)
I do not trust a vaccine unless it has already been safely given to millions of other people.4644520.011.26 (0.97–1.62)
I am concerned about some of the ingredients in vaccines.4745520.011.41 (1.09–1.81)
 Vaccine recommendations from the Centers for Disease Control and Prevention (CDC) are a good fit for me.7272740.311.14 (0.85–1.52)
I am concerned that the government and drug companies experiment on people like me.4139470.011.25 (0.96–1.62)
 The benefits of vaccines are much bigger than their risks.7878790.901.18 (0.86–1.61)
Red text indicates survey items reflecting negative vaccine attitudes. a Column percentages (of total sample N = 2561), weighted for national representativeness. b Column percentages (of parent status) (except for the first row, “All”, which is a row percentage), weighted for national representativeness. c Using the Pearson chi-square test; bold indicates statistical significance (p < 0.05). d Adjusted Odds Ratio (95% Confidence Interval) of reporting agreement with the survey item in each row comparing parents of at least one child <18 years of age to other adults, adjusted for the sociodemographic characteristics significantly associated with parental status in Table 2 (i.e., age, education, race/ethnicity); for example, parents of at least one child <18 years of age had 50% greater odds of having had COVID-19 disease than non-parents (after adjusting for age, education, and race/ethnicity); bold indicates statistical significance (p < 0.05).

3.2.3. Vaccine Attitudes Associated with Parent Status

Parents were less likely to report that most of their friends had gotten vaccinated against COVID-19 than other adults (51% vs. 61%; aOR: 0.60; 95%CI: 0.46–0.78) or support a requirement for children to be vaccinated against COVID-19 to attend school (52% vs. 57%; aOR: 0.75; 95%CI: 0.58–0.97). Parents were more likely to report concerns about the safety of COVID-19 vaccines in children (67% vs. 58%; aOR: 1.59; 95%CI: 1.23–2.06) or vaccine ingredients (52% vs. 45%; aOR: 1.41; 95%CI: 1.09–1.81). Parents were also more likely to believe it better for children to develop immunity to COVID-19 by getting sick rather than by getting a shot (45% vs. 33%; aOR: 1.56; 95%CI: 1.20–2.02) or that COVID-19 in children is no worse than a cold or the flu (51% vs. 38%; aOR: 1.56; 95%CI: 1.22–2.01).

3.3. Routine Vaccine Intentions, Safety Concerns, and Trust in CDC by Age Groups of Interest

3.3.1. Routine Vaccine Intentions

Three-quarters (76%) of parents of preteens 11–12 years old intended for that child to receive all recommended vaccines in adolescence; 22% were unsure or intended to skip some adolescent vaccines, and 2% intended to skip all adolescent vaccines (Table 4). Four-fifths (80%) of parents of children under 5 years old (who did not also have a child 11–12 years old) intended for that child to receive all recommended vaccines in childhood; 18% were unsure or intended to skip some childhood vaccines, and 2% intended to skip all childhood vaccines. In contrast, two-fifths (41%) of adults 18–50 years old (who did not have a child 0–5 or 11–12 years old) intended to receive all vaccines recommended for young adults, while 41% were unsure or intended to skip some adult vaccines, and 18% intended to receive no adult vaccines; 54% of adults over 50 years old (who did not have a child 0–5 or 11–12 years old) intended to receive all vaccines recommended for older adults, while 38% were unsure or intended to skip some adult vaccines, and 9% intended to receive no adult vaccines.
Table 4. Routine vaccine intentions and safety concerns of parents and other adults, stratified by age groups most relevant to vaccine schedule.
Table 4. Routine vaccine intentions and safety concerns of parents and other adults, stratified by age groups most relevant to vaccine schedule.
Survey Items (by Age Group) aResponseTotal (%) bIntentions to Get Recommended Vaccines (%) cp-Value d
AllSome/UnsureNone
Parents of Children <5 Years (n = 231) 1180182
My child does not like needles.Disagree20643330.02
Agree8084152
I am confident I can get my child vaccinated if I so choose—I know where to get vaccines I can afford, and I have transportation to get there.Disagree6335512<0.01
Agree9483161
I have most of the important information I need to make a decision about vaccinating my child.Disagree1146504<0.01
Agree8984152
I am confident that getting the recommended vaccines is safe for my child.Disagree13177211<0.01
Agree8789101
Among those not confident in vaccine safety…
I worry that the ingredients in vaccines are unnatural or unsafe for my child.Disagree26581140.38
Agree7421699
I worry about my child developing autism because of vaccines.Disagree65197560.55
Agree35146917
I worry about the serious side effects of vaccines.Disagree2848690.29
Agree72226711
I worry about my child getting too many vaccines at once.Disagree38384130.13
Agree6226659
It is better to develop immunity by getting sick rather than by getting a shot.Disagree56483130.04
Agree4433598
The flu vaccine is made with eggs, which my child is allergic to.Disagree792268100.42
Agree210928
The flu vaccine has thimerosal in it, which is dangerous.Disagree602367100.57
Agree4098110
The flu vaccine will make my child sick with the flu.Disagree51584110.10
Agree4930628
I worry about outbreaks of disease from vaccines.Disagree64177760.59
Agree36176617
There is less disease nowadays because of better sanitation, not because of vaccines.Disagree732367100.33
Agree2708812
I don’t see the point of vaccinating against diseases that are so rare.Disagree72226990.30
Agree2857916
Scales
Trust in the Centers for Disease Control and Prevention (CDC)Low3567303<0.01
High6587111
Parents of Preteens 11–12 Years (n = 135) 576222
My child does not like needles.Disagree23623350.04
Agree7781190
I am confident I can get my child vaccinated if I so choose—I know where to get vaccines I can afford, and I have transportation to get there.Disagree608713<0.01
Agree9481181
I have most of the important information I need to make a decision about vaccinating my child.Disagree508515<0.01
Agree9580191
I am confident that getting the recommended vaccines is safe for my child.Disagree1710837<0.01
Agree8390100
Among those not confident in vaccine safety…
I worry that the ingredients in vaccines are unnatural or unsafe for my child.Disagree242962100.13
Agree764897
I worry about the serious side effects of vaccines.Disagree33227170.33
Agree675887
I worry about my child getting too many vaccines at once.Disagree14083170.62
Agree8612826
It is better to develop immunity by getting sick rather than by getting a shot.Disagree461871110.22
Agree543924
The flu vaccine is made with eggs, which my child is allergic to.Disagree88108370.94
Agree12117911
The flu vaccine has thimerosal in it, which is dangerous.Disagree741179110.67
Agree2613870
The flu vaccine will make my child sick with the flu.Disagree641375110.33
Agree365950
I worry about outbreaks of disease from vaccines.Disagree681277110.41
Agree326940
There is less disease nowadays because of better sanitation, not because of vaccines.Disagree44381170.09
Agree5616840
I don’t see the point of vaccinating against diseases that are so rare.Disagree82108190.74
Agree1811890
I am concerned about the HPV vaccine in particular.Disagree521868140.06
Agree481990
Among those concerned about the HPV vaccine in particular…
I worry that the HPV vaccine is too new.Disagree4801001000.47
Agree52397100
I worry that the HPV vaccine could cause my child to develop chronic fatigue syndrome.Disagree6301001000.31
Agree37496100
I worry that the HPV vaccine could increase my child’s sexual activity.Disagree762981000.68
Agree240100100
I worry that the HPV vaccine could cause my child to become infertile.Disagree6501001000.30
Agree35496100
Scales
Trust in the Centers for Disease Control and Prevention (CDC)Low3553434<0.01
High6588111
Adults 18–50 Years (n = 887) 52414118
I wish I better understood how vaccines actually work.Disagree564139200.10
Agree44414514
I wish I better understood how vaccines are made and tested.Disagree414338190.24
Agree59404416
I wish I better understood all the different types of vaccines.Disagree424038220.05
Agree58424314
I am less than 25 years old and have never received an HPV vaccine.Disagree62464940.01
Agree38304723
I do not like needles.Disagree464240190.67
Agree54414316
I am confident I can get vaccinated if I so choose—I know where to get vaccines I can afford, and I have transportation to get there.Disagree10125731<0.01
Agree90444016
I have most of the important information I need to make a decision about vaccination.Disagree102255220.01
Agree90434017
I am confident that getting the recommended vaccines is safe for me.Disagree2464648<0.01
Agree7652408
Among those not confident in vaccine safety…
I worry that the ingredients in vaccines are unnatural or unsafe.Disagree22754390.57
Agree7854451
I worry about the serious side effects of vaccines.Disagree17660340.38
Agree8364351
It is better to develop immunity by getting sick rather than by getting a shot.Disagree30145728<0.01
Agree7024157
The flu vaccine is made with eggs, which I’m allergic to.Disagree94547480.19
Agree6194240
The flu vaccine has thimerosal in it, which is dangerous.Disagree601048410.04
Agree4004258
The flu vaccine will make me sick with the flu.Disagree50847440.34
Agree5034453
I worry about outbreaks of disease from vaccines.Disagree49850420.32
Agree5144056
There is less disease nowadays because of better sanitation, not because of vaccines.Disagree48947440.24
Agree5224454
I don’t see the point of vaccinating against diseases that are so rare.Disagree5885835<0.01
Agree4232870
Scales
Trust in the Centers for Disease Control and Prevention (CDC)Low33214435<0.01
High6752408
Adults >50 Years (n = 1279) 4854389
I wish I better understood how vaccines actually work.Disagree535435110.01
Agree4754406
I wish I better understood how vaccines are made and tested.Disagree44612911<0.01
Agree5649447
I wish I better understood all the different types of vaccines.Disagree425633110.02
Agree5853417
I do not like needles.Disagree555139100.13
Agree4557367
I am confident I can get vaccinated if I so choose—I know where to get vaccines I can afford, and I have transportation to get there.Disagree3284329<0.01
Agree9755378
I have most of the important information I need to make a decision about vaccination.Disagree7216910<0.01
Agree9356359
I am confident that getting the recommended vaccines is safe for me.Disagree2336136<0.01
Agree7769301
Among those not confident in vaccine safety…
I worry that the ingredients in vaccines are unnatural or unsafe.Disagree14168310.44
Agree8635937
I worry about the serious side effects of vaccines.Disagree9372240.47
Agree9136037
It is better to develop immunity by getting sick rather than by getting a shot.Disagree3187418<0.01
Agree6915445
The flu vaccine is made with eggs, which I’m allergic to.Disagree9326138<0.01
Agree7206218
The flu vaccine has thimerosal in it, which is dangerous.Disagree60264340.17
Agree4065539
The flu vaccine will make me sick with the flu.Disagree66367300.08
Agree3434947
I worry about outbreaks of disease from vaccines.Disagree64265330.22
Agree3645243
There is less disease nowadays because of better sanitation, not because of vaccines.Disagree49561340.28
Agree5116137
I don’t see the point of vaccinating against diseases that are so rare. Disagree53565290.02
Agree4715743
Scales
Trust in the Centers for Disease Control and Prevention (CDC)Low25165925<0.01
High7569292
a Each survey respondent (N = 2561) only received the above survey items for one of the four age groups, with priority given to the smallest group, to avoid redundancy and an unnecessarily long survey while maintaining power for precise estimates within each group. So, although all respondents received additional survey items, respondents who were parents of children both 0–5 years old and 11–12 years old were only given the additional survey items corresponding to the 11–12 age group, and adults 18–50 who were also parents of children 0–5 years old were only given the additional survey items corresponding to the 0–5 age group. The exception is the scale items that went to the entire sample. b Column percentages of the total sample for each age group, and of the total in the corresponding (mutually exclusive) age group for each survey item, weighted for national representativeness. c Row percentages of intentions to get vaccines recommended for each (mutually exclusive) age group by agreement with survey item, weighted for national representativeness. For parents of children <5 years of age, we asked their intentions to get those children the vaccines recommended for them at this age; for parents of children 11–12 years of age, we asked their intentions to get those children the vaccines recommended for them at this age; for adults 18–50, we asked their intentions to get themselves the vaccines recommended for them at this age (e.g., annual flu and Tdap every 10 years); for adults >50, we asked their intentions to get themselves the vaccines recommended for them at this age. d Using the Pearson chi-square test; bold indicates statistical significance (p < 0.05).

3.3.2. Vaccine Safety Concerns

Most parents of preteens 11–12 years old (83%) and other parents of children under 5 years old (87%) were confident in the safety of the vaccines recommended for their child; about three-quarters of other adults (76% of adults 18–50, 77% of adults over 50) were confident in the safety of the vaccines recommended for themselves. Confidence in routine vaccine safety was strongly correlated with intending to receive routine vaccines among all four age groups (p < 0.01).
The most prevalent specific vaccine concerns among parents of preteens 11–12 years old who were not confident in vaccine safety included worrying about their child getting too many vaccines at once (86%), their child not liking needles (77%), worrying that the ingredients in vaccines are unnatural or unsafe (76%), and worrying about the serious side effects of vaccines (67%). About half of parents of preteens 11–12 years old who were not confident in vaccine safety believed it better to develop immunity by getting sick rather than by getting a shot (54%) and that there is less disease nowadays because of better sanitation, not because of vaccines (56%). The most prevalent vaccine concerns among other parents of children 0–5 years old who were not confident in vaccine safety were the same: not liking needles (80%), ingredients (74%), serious side effects (72%), and getting too many vaccines at once (62%). Nearly half of other parents of children 0–5 years old who were not confident in vaccine safety believed that the flu vaccine would make their child sick with the flu (49%) and that it is better to develop immunity by getting sick rather than by getting a shot (44%).
The most prevalent vaccine concerns among other adults who were not confident in vaccine safety included: serious side effects (83% of adults 18–50, 91% of adults over 50), ingredients (78% of adults 18–50, 86% of adults over 50), and preferring to develop immunity by getting sick rather than by vaccinating (70% of adults 18–50, 69% of adults over 50). About half of other adults did not like needles (54% of adults 18–50, 45% of adults over 50), believed modern disease control to be due to sanitation, not vaccines (52% of adults 18–50, 51% of adults over 50), and did not see the point of vaccinating against rare diseases (42% of adults 18–50, 47% of adults over 50). About half of other adults 18–50 and about one-third of other adults over 50 worried about outbreaks of disease from vaccines (51% and 36%, respectively) and believed flu vaccines would give them the flu (50% and 34%, respectively). Two-fifths (40%) of other adults worried about the dangers of flu vaccines containing thimerosal. Very few other adults were concerned about allergic reactions to eggs in flu vaccines (6% of adults 18–50, 7% of adults over 50).

3.3.3. Trust in CDC

About two-thirds of parents of preteens 11–12 years old (65%), other parents of children 0–5 years old (65%), and other adults 18–50 years old (67%) had high trust in the CDC. Three-quarters (75%) of adults over 50 years old had high trust in CDC. Trust in CDC was strongly correlated with intending to receive routine vaccines among all four age groups (p < 0.01).

4. Discussion

Parents of children were less likely to be up-to-date on their COVID-19 vaccines than other adults and more likely to report ever having COVID-19 disease. Parents were more likely to report concerns about vaccine safety and ingredients and perceive COVID-19 in children to be no worse than a cold or the flu. Parents were less likely to support COVID-19 vaccine school requirements and to perceive high vaccine coverage among their friends. However, more than three-quarters of parents of children aged 0–5 or 11–12 (ages at which most routine vaccines are due) intended for their child to receive all recommended vaccines for their age, whereas only about half of adults without children these ages intended to receive all recommended vaccines themselves.
These findings mostly align with data from our previous surveys. In our September 2021 survey, parents were less likely to be vaccinated against COVID-19 and more likely to report concerns about vaccine safety and perceive low COVID-19 disease severity than other adults, though parents were no more likely than other adults to report having had COVID-19 disease at that point [22]. We hypothesized at the time that parents may have had more preexisting vaccine hesitancy prior to the pandemic than non-parents, perhaps due to a greater flow of vaccine misinformation among parent social circles or negative experiences vaccinating their children. Parent concerns reflect those of the general US population, albeit often more prevalent [21,25,34].
Some of these concerns are also understandably and unsurprisingly higher among parents, given the circumstances of the COVID-19 pandemic and parents’ experiences during it. For example, parents likely perceive COVID-19 to be more similar to routine winter colds than other adults because COVID-19 is typically less severe among children and young adults than older adults [10], and so parents’ personal experiences with COVID-19 (whether among themselves or their children) may have been less severe than the experiences of other adults. Additionally, parents likely perceive lower vaccine coverage among their friends because many of their friends are also parents, among whom vaccine coverage is lower. COVID-19 vaccines have also been studied more thoroughly among adults than among children, with the initial clinical trials and EUAs focusing on persons at least 16 years of age [1,5,7,35,36], potentially explaining the greater frequency of vaccine safety concerns among parents compared to other adults.
These findings also highlight an interesting contrariety: parents are less confident in vaccines than other adults, and COVID-19 vaccine coverage is much higher among adults than children [10], yet routine (non-COVID-19) vaccine coverage among adults [37] is far lower than among children [38]. For example, among children born during 2018 or 2019, primary series completion by 2 years of age was above 90% for most common childhood vaccines, such as hepatitis B, polio, measles/mumps/rubella (MMR), and varicella, and 64% had received at least two doses of influenza vaccine [39]. In contrast, only 14% of US adults had received all age-appropriate vaccines in 2018, with coverage rates of 46% for influenza, 63% for tetanus, 69% for pneumococcal (among adults over 65), and 24% for herpes zoster (among adults over 50) [40]. However, this apparent contradiction is likely explained by convenience and expectation; most children see their pediatrician regularly and are given routine vaccines as part of the long-established standard of care, whereas many adults (especially younger adults) do not regularly see a doctor and thus often must seek out their own vaccination independently.

4.1. Implications

Vaccinated parents are far more likely to intend to vaccinate their children than unvaccinated parents [22]. Thus, improving vaccine coverage and attitudes among parents should also increase the likelihood that these parents will vaccinate their children. Messaging and outreach should support decision-making by emphasizing vaccine effectiveness and addressing concerns with sensitivity and clarity. Since healthcare providers are the most common and credible source of vaccine information for parents [41,42], especially as opposed to government or pharmaceutical companies, public health should prioritize supplying useful resources to healthcare providers to aid in their support of the vaccine decision-making of their patients (or their patients’ parents). Such resources should be updated regularly to reflect new circulating strains, authorized vaccines, and/or public safety concerns.

4.2. Strengths and Limitations

The CDC now considers everyone 6 years and older to be “up-to-date” if they have received an updated COVID-19 vaccine (children 6 months to 5 years may need multiple doses to be up to date, but at least one dose must be the updated COVID-19 vaccine) [9,43]. However, when this survey was administered in September 2022, “up-to-date” was defined as fully vaccinated (with a primary series) and boosted. No specification was made regarding whether the booster must be the most recent version, as the bivalent booster was not yet widely available, having just been authorized [7]. Thus, we are unable to differentiate between booster versions in our data and assume that our measure of “up-to-date” refers largely to the now obsolete monovalent booster. However, our survey was also well-timed to capture the proportion of US parents and other adults who had received a monovalent booster dose just before it was replaced by the updated bivalent version.
Another limitation of our study is its reliance on data from one point in time rather than over an extended period. Our data are also subject to the limitations of self-reporting. However, most analyses of COVID-19 vaccine attitudes do not cover routine vaccines, nor have they focused on parents in particular, as ours does. Furthermore, many other analyses of COVID-19 vaccine attitudes have not been subjected to peer review, and their internal and external validity varies widely. A strength of this analysis is its use of high-quality data from a well-established nationally representative panel.

5. Conclusions

Immunization programs must reemphasize and sustain efforts to support parents as they make vaccine decisions both for themselves and their children. The public health community should ensure pediatric providers have the resources needed to discuss the risks and benefits of vaccines with their patients’ parents, especially as new vaccines are authorized, and recommendations are updated.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/vaccines11121735/s1, Table S1: STROBE Statement; Table S2: Vaccine attitudes and values of parents of older children (at least 11 years of age) versus parents of younger children (0–10 years of age).

Author Contributions

Conceptualization and study design, M.Z.D. and D.A.S.; designed data collection instruments, M.Z.D., H.B.S., M.G., J.S., and D.A.S.; data collection coordination and supervision, M.Z.D., H.B.S., and D.A.S.; formal analysis, M.Z.D.; writing—original draft preparation, M.Z.D.; writing—review and editing, M.Z.D., H.B.S., M.G., J.S., and D.A.S.; funding acquisition, D.A.S. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported in part by a research grant from the Investigator-Initiated Studies Program of Merck Sharp & Dohme LLC. The opinions expressed in this paper are those of the authors and do not necessarily represent those of Merck Sharp & Dohme LLC. Merck Sharp & Dohme LLC was not involved in any aspects of the study, including the study design; data collection, analyses, and interpretation; the writing of the research article; and the decision to submit the article for publication.

Institutional Review Board Statement

The Johns Hopkins Bloomberg School of Public Health Institutional Review Board considered this work to be public health surveillance and not human subject research.

Informed Consent Statement

Participants were members of the Ipsos KnowledgePanel and gave their consent to be surveyed.

Data Availability Statement

Deidentified individual participant data will not be made available. The data are not publicly available to protect participant confidentiality.

Conflicts of Interest

Matthew Dudley has received research support from Merck. Daniel Salmon has received research support from Merck and serves on advisory boards for Merck, Janssen, Sanofi, and Moderna. Matthew Dudley and Daniel Salmon have received funding from the Vaccination Confidence Fund, which is jointly funded by Facebook and Merck. Holly Schuh served as a (paid) health advisor to the University of Roehampton who provided guidance on recovery-building and future pandemic preparedness (including views on vaccines/vaccination) and understanding citizen engagement in the G7 in 2021–22 (during the presented study). Jana Shaw serves as a consultant to Pfizer on the meningococcal B vaccine. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Matthew Dudley wrote the first draft of the manuscript; no honorarium, grant, or other form of payment was given to anyone to produce the manuscript. The funders had no role in the design of the study; in the collection, analysis, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

  1. Food and Drug Administration. FDA Takes Key Action in Fight Against COVID-19 by Issuing Emergency Use Authorization for First COVID-19 Vaccine. 2020. Available online: https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19 (accessed on 17 November 2023).
  2. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents in Another Important Action in Fight Against Pandemic. 2021. Available online: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use (accessed on 17 November 2023).
  3. Food and Drug Administration. FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children 5 through 11 Years of Age. 2021. Available online: https://www.fda.gov/news-events/press-announcements/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age (accessed on 17 November 2023).
  4. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children Down to 6 Months of Age. 2022. Available online: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-and-pfizer-biontech-covid-19-vaccines-children (accessed on 17 November 2023).
  5. Food and Drug Administration. FDA Takes Additional Action in Fight Against COVID-19 by Issuing Emergency Use Authorization for Second COVID-19 Vaccine. 2020. Available online: https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid (accessed on 17 November 2023).
  6. Food and Drug Administration. FDA Roundup: July 8, 2022. 2022. Available online: https://www.fda.gov/news-events/press-announcements/fda-roundup-july-8-2022 (accessed on 17 November 2023).
  7. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose. 2022. Available online: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use (accessed on 17 November 2023).
  8. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose in Younger Age Groups. 2022. Available online: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-and-pfizer-biontech-bivalent-covid-19-vaccines (accessed on 17 November 2023).
  9. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Changes to Simplify Use of Bivalent mRNA COVID-19 Vaccines. 2023. Available online: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-changes-simplify-use-bivalent-mrna-covid-19-vaccines (accessed on 17 November 2023).
  10. Centers for Disease Control and Prevention. COVID Data Tracker; Centers for Disease Control and Prevention: Atlanta, GA, USA, 2023.
  11. Hammershaimb, E.A.; Cole, L.D.; Liang, Y.; Hendrich, M.A.; Das, D.; Petrin, R.; Cataldi, J.R.; O’Leary, S.T.; Campbell, J.D. COVID-19 Vaccine Acceptance Among US Parents: A Nationally Representative Survey. J. Pediatr. Infect. Dis. Soc. 2022, 11, 361–370. [Google Scholar] [CrossRef]
  12. Gidengil, C.; Chen, C.; Parker, A.M.; Nowak, S.; Matthews, L. Beliefs around childhood vaccines in the United States: A systematic review. Vaccine 2019, 37, 6793–6802. [Google Scholar] [CrossRef]
  13. Opel, D.J.; Furniss, A.; Zhou, C.; Rice, J.D.; Spielvogle, H.; Spina, C.; Perreira, C.; Giang, J.; Dundas, N.; Dempsey, A.; et al. Parent Attitudes Towards Childhood Vaccines After the Onset of SARS-CoV-2 in the United States. Acad. Pediatr. 2022, 22, 1407–1413. [Google Scholar] [CrossRef]
  14. Van Bavel, J.J.; Pretus, C.; Rathje, S.; Pärnamets, P.; Vlasceanu, M.; Knowles, E.D. The Costs of Polarizing a Pandemic: Antecedents, Consequences, and Lessons. Perspect. Psychol. Sci. A J. Assoc. Psychol. Sci. 2023, 17456916231190395. [Google Scholar] [CrossRef]
  15. World Health Organization. Pandemic Fatigue—Reinvigorating the Public to Prevent COVID-19: Policy Framework for Supporting Pandemic Prevention and Management; World Health Organization: Geneva, Switzerland, 2020.
  16. Dhanani, L.Y.; Franz, B. A meta-analysis of COVID-19 vaccine attitudes and demographic characteristics in the United States. Public Health 2022, 207, 31–38. [Google Scholar] [CrossRef]
  17. Howard, M.C. Investigating the Relation of Political Orientation and Vaccination Outcomes: Identifying the Roles of Political Ideology, Party Affiliation, and Vaccine Hesitancy. Psychol. Rep. 2022, 332941221144604. [Google Scholar] [CrossRef]
  18. Seither, R.; Calhoun, K.; Yusuf, O.B.; Dramann, D.; Mugerwa-Kasujja, A.; Knighton, C.L.; Black, C.L. Vaccination Coverage with Selected Vaccines and Exemption Rates Among Children in Kindergarten—United States, 2021–2022 School Year. MMWR. Morb. Mortal. Wkly. Rep. 2023, 72, 26–32. [Google Scholar] [CrossRef]
  19. Patel Murthy, B.; Zell, E.; Kirtland, K.; Jones-Jack, N.; Harris, L.; Sprague, C.; Schultz, J.; Le, Q.; Bramer, C.A.; Kuramoto, S.; et al. Impact of the COVID-19 Pandemic on Administration of Selected Routine Childhood and Adolescent Vaccinations—10 U.S. Jurisdictions, March-September 2020. MMWR. Morb. Mortal. Wkly. Rep. 2021, 70, 840–845. [Google Scholar] [CrossRef]
  20. McNally, V.V.; Bernstein, H.H. The Effect of the COVID-19 Pandemic on Childhood Immunizations: Ways to Strengthen Routine Vaccination. Pediatr. Ann. 2020, 49, e516–e522. [Google Scholar] [CrossRef]
  21. Dudley, M.Z.; Schwartz, B.; Brewer, J.; Kan, L.; Bernier, R.; Gerber, J.E.; Ni, H.B.; Proveaux, T.M.; Rimal, R.N.; Salmon, D.A. COVID-19 Vaccination Status, Attitudes, and Values among US Adults in September 2021. J. Clin. Med. 2022, 11, 3734. [Google Scholar] [CrossRef]
  22. Dudley, M.Z.; Schwartz, B.; Brewer, J.; Kan, L.; Bernier, R.; Gerber, J.E.; Ni, H.B.; Proveaux, T.M.; Rimal, R.N.; Salmon, D.A. COVID-19 Vaccination Attitudes, Values, Intentions: US parents for their children, September 2021. Vaccine 2023. [Google Scholar] [CrossRef]
  23. Dudley, M.Z.; Schuh, H.B.; Shaw, J.; Salmon, D.A. Attitudes and Values of US Adults Not Yet Up-to-Date on COVID-19 Vaccines in September 2022. J. Clin. Med. 2023, 12, 3932. [Google Scholar] [CrossRef]
  24. Ipsos. KnowledgePanel. Available online: https://www.ipsos.com/en-us/solutions/public-affairs/knowledgepanel (accessed on 20 January 2023).
  25. Salmon, D.A.; Dudley, M.Z.; Brewer, J.; Kan, L.; Gerber, J.E.; Budigan, H.; Proveaux, T.M.; Bernier, R.; Rimal, R.; Schwartz, B. COVID-19 vaccination attitudes, values and intentions among United States adults prior to emergency use authorization. Vaccine 2021, 39, 2698–2711. [Google Scholar] [CrossRef]
  26. Zapf, A.J.; Schuh, H.; Rimal, R.; Harvey, S.A.; Shaw, J.; Balgobin, K.; Salmon, D.A. Knowledge, Attitudes, and Intentions Regarding COVID-19 Vaccination in the General Population and the Effect of Different Framing Messages for a Brief Video on Intentions to Get Vaccinated among Unvaccinated Individuals in the United States during July 2021; Social Sciences Research Network (SSRN): Atlanta, GA, USA. Available online: https://ssrn.com/abstract=4152703 (accessed on 17 November 2023).
  27. STROBE. Available online: https://www.strobe-statement.org/ (accessed on 1 November 2023).
  28. Holroyd, T.A.; Limaye, R.J.; Gerber, J.E.; Rimal, R.N.; Musci, R.J.; Brewer, J.; Sutherland, A.; Blunt, M.; Geller, G.; Salmon, D.A. Development of a Scale to Measure Trust in Public Health Authorities: Prevalence of Trust and Association with Vaccination. J. Health Commun. 2021, 26, 272–280. [Google Scholar] [CrossRef]
  29. Centers for Disease Control and Prevention. Child and Adolescent Immunization Schedule by Age. Available online: https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html (accessed on 27 April 2023).
  30. Centers for Disease Control and Prevention. Adult Immunization Schedule by Age. Available online: https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html (accessed on 27 April 2023).
  31. Rosenstock, I.M. Historical Origins of the Health Belief Model. Health Educ. Monogr. 1974, 2, 328–335. [Google Scholar] [CrossRef]
  32. Kumar, S.; Quinn, S.C.; Kim, K.H.; Musa, D.; Hilyard, K.M.; Freimuth, V.S. The Social Ecological Model as a Framework for Determinants of 2009 H1N1 Influenza Vaccine Uptake in the United States. Health Educ. Behav. 2012, 39, 229–243. [Google Scholar] [CrossRef]
  33. StataCorp LLC. STATA. Available online: https://www.stata.com/ (accessed on 20 January 2023).
  34. Kaiser Family Foundation. KFF COVID-19 Vaccine Monitor Dashboard. Available online: https://www.kff.org/coronavirus-covid-19/dashboard/kff-covid-19-vaccine-monitor-dashboard/ (accessed on 10 November 2023).
  35. Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Pérez Marc, G.; Moreira, E.D.; Zerbini, C.; et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020, 383, 2603–2615. [Google Scholar] [CrossRef]
  36. Baden, L.R.; El Sahly, H.M.; Essink, B.; Kotloff, K.; Frey, S.; Novak, R.; Diemert, D.; Spector, S.A.; Rouphael, N.; Creech, C.B.; et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2020, 384, 403–416. [Google Scholar] [CrossRef]
  37. Centers for Disease Control and Prevention. AdultVaxView. Available online: https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/index.html (accessed on 2 May 2023).
  38. Centers for Disease Control and Prevention. ChildVaxView. Available online: https://www.cdc.gov/vaccines/imz-managers/coverage/childvaxview/index.html (accessed on 2 May 2023).
  39. Hill, H.A.; Chen, M.; Elam-Evans, L.D.; Yankey, D.; Singleton, J.A. Vaccination Coverage by Age 24 Months Among Children Born During 2018-2019—National Immunization Survey-Child, United States, 2019–2021. MMWR. Morb. Mortal. Wkly. Rep. 2023, 72, 33–38. [Google Scholar] [CrossRef]
  40. Lu, P.J.; Hung, M.C.; Srivastav, A.; Grohskopf, L.A.; Kobayashi, M.; Harris, A.M.; Dooling, K.L.; Markowitz, L.E.; Rodriguez-Lainz, A.; Williams, W.W. Surveillance of Vaccination Coverage Among Adult Populations-United States, 2018. Morb. Mortal. Wkly. Report. Surveill. Summ. 2021, 70, 1–26. [Google Scholar] [CrossRef]
  41. Freed, G.L.; Clark, S.J.; Butchart, A.T.; Singer, D.C.; Davis, M.M. Sources and perceived credibility of vaccine-safety information for parents. Pediatrics 2011, 127 (Suppl. 1), S107–S112. [Google Scholar] [CrossRef]
  42. Chung, Y.; Schamel, J.; Fisher, A.; Frew, P.M. Influences on Immunization Decision-Making among US Parents of Young Children. Matern. Child Health J. 2017, 21, 2178–2187. [Google Scholar] [CrossRef]
  43. Centers for Disease Control and Prevention. Stay up to Date with COVID-19 Vaccines Including Boosters. Available online: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html (accessed on 2 May 2023).
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Dudley, M.Z.; Schuh, H.B.; Goryn, M.; Shaw, J.; Salmon, D.A. Attitudes toward COVID-19 and Other Vaccines: Comparing Parents to Other Adults, September 2022. Vaccines 2023, 11, 1735. https://doi.org/10.3390/vaccines11121735

AMA Style

Dudley MZ, Schuh HB, Goryn M, Shaw J, Salmon DA. Attitudes toward COVID-19 and Other Vaccines: Comparing Parents to Other Adults, September 2022. Vaccines. 2023; 11(12):1735. https://doi.org/10.3390/vaccines11121735

Chicago/Turabian Style

Dudley, Matthew Z., Holly B. Schuh, Michelle Goryn, Jana Shaw, and Daniel A. Salmon. 2023. "Attitudes toward COVID-19 and Other Vaccines: Comparing Parents to Other Adults, September 2022" Vaccines 11, no. 12: 1735. https://doi.org/10.3390/vaccines11121735

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop